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Abstract
Background:  Lipoprotein lipase (LPL) is anchored at the vascular endothelium through
interaction with heparan sulfate. It is not known how this enzyme is turned over but it has been
suggested that it is slowly released into blood and then taken up and degraded in the liver. Heparin
releases the enzyme into the circulating blood. Several lines of evidence indicate that this leads to
accelerated flux of LPL to the liver and a temporary depletion of the enzyme in peripheral tissues.
Results:  Rat livers were found to contain substantial amounts of LPL, most of which was
catalytically inactive. After injection of heparin, LPL mass in liver increased for at least an hour. LPL
activity also increased, but not in proportion to mass, indicating that the lipase soon lost its activity
after being bound/taken up in the liver. To further study the uptake, bovine LPL was labeled with
125I and injected. Already two min after injection about 33 % of the injected lipase was in the liver
where it initially located along sinusoids. With time the immunostaining shifted to the hepatocytes,
became granular and then faded, indicating internalization and degradation. When heparin was
injected before the lipase, the initial immunostaining along sinusoids was weaker, whereas staining
over Kupffer cells was enhanced. When the lipase was converted to inactive before injection, the
fraction taken up in the liver increased and the lipase located mainly to the Kupffer cells.
Conclusions: This study shows that there are heparin-insensitive binding sites for LPL on both
hepatocytes and Kupffer cells. The latter may be the same sites as those that mediate uptake of
inactive LPL. The results support the hypothesis that turnover of endothelial LPL occurs in part by
transport to and degradation in the liver, and that this transport is accelerated after injection of
heparin.
Background
Lipoprotein lipase (LPL) hydrolyses triglycerides in chy-
lomicrons and VLDL and thereby makes fatty acids avail-
able for cellular uptake and use in metabolic processes
[1,2]. Relatively high levels of LPL mRNA are found in adi-
pose tissue, heart, red skeletal muscle and lactating mam-
mary gland [3,4]. Parenchymal cells, such as adipocytes
and myocytes, synthesize and secrete the enzyme, which
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is then transferred to the endothelium and anchored to
the oligosaccharide chains of heparan sulfate proteogly-
cans (HSPG) [1,2]. There is continuous recycling of the
enzyme between the luminal and abluminal side of the
endothelial cells, and perhaps to other extracellular sites
in the tissue [1,5,6]. It is not known how the extracellular
enzyme is turned over. One possibility is that it is trans-
ported with blood to the liver and degraded there [7]. LPL
activity in the circulating blood is normally low and most
of the LPL protein in blood is catalytically inactive [7-10].
Release of lipase from extrahepatic tissues into blood has
been demonstrated [11,12]. Model studies with labeled
LPL have demonstrated uptake and degradation of both
active and inactive LPL in the liver [13-15].
Heparin releases LPL from its endothelial binding sites
into the circulating blood. The uptake in the liver is
retarded, but not abolished [13,14]. This has been taken
as evidence that there are both heparin-sensitive and
heparin-insensitive binding sites in the liver. An implica-
tion is that the high lipase activity in blood after heparin
injection is due to release from peripheral tissues com-
bined with retarded uptake in the liver. Studies in rats and
in human subjects indicate that the net effect of heparin is
an accelerated transport of LPL to the liver [16,17]. If this
hypothesis is correct, LPL mass and activity should
increase in the liver after injection of heparin, in contrast
to the decrease that occurs in extrahepatic tissues [6]. To
test these concepts we have followed LPL activity and
mass in liver after injection of heparin, and we have used
immunofluorescence to explore if heparin changes the
pattern of where in the liver LPL binds.
Results
Amount and distribution of LPL in liver
LPL activity in rat liver was 26 ± 1 mU/g (Table 1), similar
to the activity reported by Peterson et al [15]. This is low
compared to the activities in adipose tissue (around 1600
mU/g in fed rats [6]) and heart (around 1100 mU/g [18]).
LPL mass was 120 ng/g. The relation between LPL activity
and mass in plasma was similar to that in liver; activity
was 8 mU/ml and mass was 29 ng/ml (Table 1). The spe-
cific activity of the enzyme in plasma increased to around
1.2 after injection of heparin. This indicates that most of
the LPL in plasma or liver before heparin was inactive, in
accord with studies on LPL in human plasma [7-10].
To study the distribution of endogenous LPL in rat liver
we used affinity-purified chicken antibodies raised against
bovine LPL. These antibodies have previously been used
for ELISA of LPL in rat tissues [19]. There was faint
immunofluorescence in a granular pattern (green) over
hepatocytes, and stronger staining over scattered cells
(Figure 1). Some of these reacted positively with the ED2
antibodies indicating that they were Kupffer cells. Sections
treated with pre-immune IgG instead of anti-LPL (inset in
Fig 1), as well as sections where the second antibody was
omitted, showed no immunofluorescence.
Effects of heparin
LPL activity and mass in plasma increased many-fold after
heparin injection (Table 1). The highest value was at 15
min, but even after 60 min the activity was still more then
50-fold higher than in normal plasma. In liver the level of
LPL activity had increased already two min after heparin
injection and it was about 10-fold increased both at 15
and 60 min compared to time 0. The amount of LPL pro-
tein in the liver, measured by the ELISA, had increased
about two-fold at two min, 3.5-fold at 15 min and five-
fold after 60 min. These data give direct evidence that after
injection of heparin some of the LPL released into plasma
was taken up by the liver.
Hepatic lipase (HL) was also measured in the livers (Table
1). As expected, but in sharp contrast to what was found
for LPL, the HL activity decreased after heparin. Already
after two min the activity had decreased by two thirds.
This reflects the release of HL into the circulating blood.
The activity in liver remained constant at 15 min and had
begun to increase again after 60 min.
The pattern of immunofluorescence for LPL after heparin
was similar to that before heparin, with faint staining over
most cells and more intense staining over scattered cells,
some of which were ED2 positive (not shown).
To explore the origin of the LPL released into plasma and
taken up by the liver we measured LPL activity in heart
and adipose tissue before and 20 min after injection of
heparin (Table 2). Data for plasma and liver in fed rats
were similar to those in the experiment in Table 1. In
fasted rats, plasma post-heparin LPL activity was less than
half of that in fed rats in accord with previous studies
[18,20]. The LPL activity in liver increased after heparin, in
concert with the results in Table 1. There was no statisti-
cally significant difference of the LPL activity in liver
between fed and fasted rats either before or after heparin.
In adipose tissue the LPL activity was about 5-fold higher
in fed compared to fasted rats. Heparin caused a washout
of 45 % of the LPL activity from epididymal and 65%
from perirenal adipose tissue (p < 0.01). Values for LPL
activity in heart were somewhat higher in fasted than in
fed rats, but this did not reach statistical significance (p =
0.16). Heparin caused no significant decrease of heart LPL
in fed rats, but a highly significant (p < 0.01) washout in
the fasted rats, about 40%.
Injection of labelled bovine LPL
The immunostaining of endogeneous LPL was faint and
not suitable for detailed analysis or quantitation. TheBMC Physiology 2004, 4:13 http://www.biomedcentral.com/1472-6793/4/13
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Table 1: Lipases in plasma and liver after injection of heparin
Time min Plasma Liver
LPL LPL HL
Activity mU/ml mass ng/ml spec act mU/ng activity mU/ml mass ng/ml spec act mU/ng activity mU/g
0 8 ± 2 29 ± 1 0.28 ± 0.06 26 ± 1 119 ± 12 0.22 ± 0.02 450 ± 21
2 844 ± 35 746 ± 62 1.17 ± 0.11 116 ± 21 243 ± 19 0.46 ± 0.04 181 ± 22
15 1161 ± 146 1047 ± 190 1.18 ± 0.11 245 ± 30 397 ± 37 0.62 ± 0.05 181 ± 23
60 485 ± 124 502 ± 118 1.24 ± 0.15 265 ± 27 624 ± 66 0.45 ± 0.06 255 ± 17
Rats were injected with heparin. After the indicated times the rats were killed, blood samples were taken from the heart and livers were removed 
and processed for determination of LPL activity and mass as described in Material and Methods. The values have been corrected for the 
contribution of blood remaining in the liver, and are means ± SEM, n = 6.
Detection of endogenous LPL in rat liver by immunofluorescence Figure 1
Detection of endogenous LPL in rat liver by immunofluorescence. Tissue sections were double-stained with chicken 
anti-LPL IgG (detected with Alexa 488-labeled goat anti-chicken antibodies (green)), and the monoclonal anti-Kupffer cell anti-
body ED2 (detected with Alexa 546-labeled goat anti-mouse antibodies (red)). All panels show sections from livers of rats that 
did not receive heparin. The magnification in panels A and B was × 20-fold whereas it was × 60 + zooming in panel C. Panel A 
shows staining only for LPL. Panel B is the same area as in A but with staining also for ED2. Panel C shows both stainings. The 
inset in panel A shows a control section with non-immune chicken IgG instead of anti-LPL.
Table 2: Effect of heparin injection on tissue LPL activities
Treatment LPL activity mU/g
Plasma Liver Heart Epididymal adipose Perirenal adipose
Fed rats
Before heparin 1.9 ± 0.2 28 ± 8 999 ± 111 1700 ± 138 1094 ± 195
After heparin 1057 ± 59a 173 ± 20a 868 ± 67 938 ± 70a 383 ± 73a
Fasted rats
Before heparin 2.5 ± 0.3 54 ± 12 1199 ± 63 345 ± 48b 188 ± 49b
After heparin 374 ± 76a,b 189 ± 21a 729 ± 70a 357 ± 56b 263 ± 28
The fasted rats had been deprived of food overnight (16 – 18 hours). The values have been corrected for the contribution of blood remaining in the 
liver, and are means ± SEM, n = 5. The difference is statistically significant (p < 0.05) a when comparing the effect of heparin,bwhen comparing the 
effect of nutritional state.BMC Physiology 2004, 4:13 http://www.biomedcentral.com/1472-6793/4/13
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reason is that the only reagents available were chicken
antibodies raised against bovine LPL. To further explore
the hepatic binding and uptake of the enzyme we there-
fore injected bovine LPL. A trace amount of 125I-labeled
LPL was included so that we could quantitate the uptake/
metabolism. Values are given in Table 3 for the times at
which localization of the lipase was studied by immun-
ofluorescence. These values agree with an earlier study
when more complete time curves were obtained [13]. For
active LPL earlier studies have shown that at short times
after injection about half of the lipase locates in extrahe-
patic tissues and about half in the liver [13,21,22]. In the
present study 33 % of the radioactivity was in liver after
two min (Table 3). This increased to 52 % after 15 min
and then decreased again to 20 % after 60 min. Heparin
slows down the clearance of LPL from the blood [13,21].
Fifteen min after injection of the labeled lipase, about half
is still in the circulating blood [13]. In our experiments 30
% was in the liver at this time (Table 3). Hence, 60 % or
more of the removal from plasma had taken place in the
liver. After 60 min radioactivity in the liver had decreased
to 23 % of the injected dose (Table 3). Earlier studies have
demonstrated that acid soluble breakdown products of
the labeled lipase appear in blood [13] and in the per-
fusion fluid in experiments with isolated livers [14].
Hence, the decrease of label in liver at longer times prob-
ably occurred through degradation of the lipase.
For inactive lipase earlier studies have shown that only a
minor fraction locates in extrahepatic tissues, and more
than 70% of the uptake occurs in the liver [13]. In the
present study, 50 % of the radioactivity was in the liver 15
min after injection, while 9 % was in the blood. After 60
min the radioactivity in the liver had decreased to 19 % of
the injected dose.
To visualize the injected bovine LPL we used rabbit anti-
bodies. These antibodies did not inhibit endogenous LPL
in rat post-heparin plasma or in extracts of adipose tissue.
No immuno-reaction was seen in sections from control
rats not injected with LPL (inset in Figure 2E). Likewise,
there was no immunofluorescence in sections treated with
non-immune rabbit IgG instead of anti-LPL, or when the
second antibody was omitted.
Two min after injection of the active lipase, intense
immuno-staining was seen along sinusoids (Figure 2A).
This staining was strongest in the periportal areas. There
was little staining outside the sinusoids. Occasionally a
few fluorescent dots were seen in hepatocytes, possibly
representing endocytic vesicles. At 15 min after injection
there was still staining over the sinusoids (Figure 2C), but
most of the staining was now associated with hepatocytes
and the number of granulae seen in hepatocytes had
increased, indicating that the lipase had been internalized
in vesicles (Figure 3A). Some cells, localized predomi-
nantly around the portal area, had many fluorescent dots.
This staining was mainly granular in contrast to the more
continuous staining over sinusoids at this time. Double
staining at 15 min after injection of LPL demonstrated
that some of these cells were ED2-positive (Figure 3A). At
60 min little or no staining remained at sinusoidal sur-
faces and the total staining had decreased (Figure 2E), but
there were still grains in cells close to the portal area. This
was probably enzyme that had been taken up in intracel-
lular vesicles and had not yet become degraded.
To get more detailed information about the binding sites
in liver we used electron microscopy. For this, bovine 125I-
labeled LPL was injected and 10 min later the livers were
fixed by perfusion. The enzyme was visualized as silver
grains by means of autoradiography (Figure 4A). Count-
ing of silver grains in the sections showed that about 55%
of the lipase was within spaces of Disse, mostly associated
with hepatocytes. Twenty-five to 30% was on the luminal
side of endothelial cells. Only about 15% was inside
hepatocytes and other cell types, probably Kupffer cells.
The pattern of distribution was quite different for the inac-
tive lipase. At the first time, two min, there was intense
staining for LPL over scattered cells concentrated to the
portal regions but very little staining over sinusoids or
hepatocytes (not shown). Double staining with the ED2
antibody showed that the intensively LPL-positive cells
were Kupffer cells. After 15 min the immunofluorescence
had changed to a more punctuate pattern that still co-
localized with Kupffer cells (Figure 5C). This indicated
Table 3: Clearance of 125I-labeled LPL from blood and uptake in 
liverin the presence and absence of heparin
Time after injection (min) % of injected 125I-labeled LPL
No heparin Heparin
Blood Liver Liver
Active LPL
2 32.6 ± 3.1 13.9 ± 0.6
15 8.5 ± 13.6 51.5 ± 2.8 30.4 ± 1.4
60 6.7 ± 5.5 18.2 ± 1.7 22.8 ± 0.4
Inactive LPL
15 9.4 ± 0.7 50.0 ± 5.5
60 6.2 ± 1.0 18.8 ± 3.1
Rats were injected with active or inactive 125I-labeled LPL either 
directly, or five min after intravenous injection of heparin. After the 
indicated times the rats were killed, blood samples were taken from 
the heart and livers were removed. The values have been corrected 
for the contribution of blood remaining in the liver, and are means ± 
SEM, n = 5.BMC Physiology 2004, 4:13 http://www.biomedcentral.com/1472-6793/4/13
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Distribution of bovine LPL in livers at different times after injection, and the effect of heparin Figure 2
Distribution of bovine LPL in livers at different times after injection, and the effect of heparin. Tissue sections 
were stained with the rabbit polyclonal anti-LPL IgG and then with goat anti-rabbit IgG labelled with Alexa fluor 488 (green). 
Panels A, C and E are from rats that did not receive heparin. Panels B, D and F are from rats that had been given heparin five 
min before the injection of active bovine LPL. Panels A and B are two min, panels C and D are 15 min, and panels E and F are 
60 min after injection of the lipase. The inset in panel E shows a section from the liver of a rat that was not injected with bovine 
LPL. The magnification was × 20.BMC Physiology 2004, 4:13 http://www.biomedcentral.com/1472-6793/4/13
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that the lipase had been internalized in vesicles. There was
some immunostaining over other cells, presumably hepa-
tocytes, but this was much weaker than the staining over
Kupffer cells (Figure 5A and 5C). After 60 min the inten-
sity of the staining had decreased, but the pattern with
more intense staining over Kupffer cells and much weaker
staining over other cells remained (not shown). Hence,
there was no indication that the inactive lipase first bound
to one type of cell and then transferred to another type for
uptake. Electron microscopic autoradiography of sections
from livers of rats ten min after injection the inactive LPL,
confirmed that the labelled lipase was mostly associated
to sinusoidal cells that morphologically seemed to resem-
ble Kupffer cells.
Heparin markedly changed the pattern of localization for
the active lipase. The initial (two min after injection)
staining along the sinusoids was much weaker than in sec-
tions from rats that had not received heparin. The staining
was generally more intense at 15 min compared to at two
min after injection of the lipase (Figure 2D). This is in
accord with the radioactivity data that showed that more
LPL had been taken up (Table 2). Compared to the pattern
without heparin, the staining was spread throughout the
liver parenchyma rather than concentrated in the portal
areas (compare Figure 2A,2C and 2E with 2B,2D and 2F).
There was more staining associated with scattered cells in
the portal areas than in sections from rats that had not
received heparin (Figure 2B). These cells were ED2-posi-
tive (not shown). Already at 15 min the LPL-staining had
taken on a granular character both in the ED2-positive
cells and in hepatocytes (Figure 3). At 60 min the intensity
of staining had decreased (Figure 2F). The ED2 positive
cells still dominated the picture but there was also granu-
lar staining over hepatocytes. More staining remained
compared to the same time point without heparin (com-
pare Figure 2F and 2E).
Electron microscopic autoradiography showed that when
heparin was injected ten min after active LPL there was a
strong reduction in the amount of LPL in the spaces of
Disse and on endothelial cells, while the radioactivity
found in hepatocytes and Kupffer cells remained (data not
shown).
Higher magnification of sections from the same experiment as in Figure 2 Figure 3
Higher magnification of sections from the same experiment as in Figure 2 Both sections are 15 min after injection 
of active bovine LPL. The rat in panel A did not receive heparin; the rat in panel B had been given heparin five min before LPL. 
Green colour represents staining of LPL by the rabbit polyclonal antibody. Red colour represents staining of Kupffer cells by 
the ED2 antibody. The magnification was × 60 + zooming.BMC Physiology 2004, 4:13 http://www.biomedcentral.com/1472-6793/4/13
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Heparin had no marked effect on the distribution of the
inactive LPL (Figure 5). Most of the staining co-localized
with staining for ED2 positive Kupffer cells (Figure 5D).
Discussion
This study shows that after injection of heparin, LPL activ-
ity and mass in liver increases several-fold, in concert with
the hypothesis that heparin causes accelerated transport of
LPL to the liver. In other parts of the body LPL is attached
to HSPG [1,2]. Heparin competes efficiently with these
binding sites. The rapid extraction of LPL by the liver in
the presence of heparin implies that some other type of
binding site must be present there. Members of the LDL
receptor (LDL-R) family bind both the active and the inac-
tive form of the lipase [23] and two recent studies indicate
that LRP is involved in hepatic uptake of LPL [24,25]. The
binding of active LPL to LRP is, however, strongly
impeded by heparin [26]. Therefore, it is unlikely that the
heparin-resistant binding of active LPL is mediated by LRP
or some other receptor of the LDL-R family.
Heparin markedly decreased the binding of LPL along the
sinusoids. This presumably reflects that binding to HSPG
was competed by heparin. Staining associated with
Kupffer-like cells increased. This may be the same sites as
those that bind inactive LPL. Another possibility is that
the LPL-heparin complexes were recognized and taken up
as such. There is evidence for binding and uptake of
heparin by Kupffer cells [27]. Most of the binding was,
however, to hepatocytes even in the presence of heparin.
Our data are qualitative, based on the immunolocaliza-
tion. For more accurate quantitation one should label the
lipase with a non-degradable label like 125I-tyramine cel-
lobiose and isolate the different cell types.
It has been suggested that LPL and HL bind, at least in
part, to the same sites in the liver [24,28]. It is, however,
unlikely that HL shares the heparin-insensitive sites. The
response of the two enzymes to heparin was very differ-
ent. HL activity decreased by 60% within two min after
heparin injection, reflecting release of the lipase into
blood. In contrast, LPL activity in the liver increased,
reflecting binding to the heparin-insensitive sites.
Earlier studies have shown that there are also heparin-sen-
sitive sites that bind LPL in liver [13]. Wallinder et al per-
fused livers in situ with heparin 15 min after injection of
125I-LPL to rats and found that about 10% of the lipase
that had bound in the liver could be released [13]. Vilaró
et al perfused isolated livers with 125I-LPL in a recirculat-
ing system for 10 min. After wash the perfusion was then
continued in single pass mode with a heparin-containing
medium. About 50% of the LPL that had bound in the
liver reappeared in the perfusion medium within four min
[14,29]. At least some of these heparin-sensitive sites are
likely HSPG, and they are probably the main sites that
mediate the initial capture of LPL from blood. This bind-
ing may correspond to the decoration of the sinusoids
seen by immunofluorescence at the earliest time after
injection of the lipase. HSPG are present on virtually all
cells in the body, including hepatocytes and endothelial
cells in the liver [30,31]. Vilaró et al studied binding and
uptake of LPL in cultured hepatocytes [32]. The enzyme
was concentrated at the tips of the microvilli, a site where
also HSPG are highly abundant [33,34]. Immunofluores-
cence now showed that at short times after injection the
lipase located along the sinusoids, and electron
Ultrastructural localization of injected bovine LPL Figure 4
Ultrastructural localization of injected bovine LPL 
125I-labeled active (upper panel) or inactive (lower panel) LPL 
was injected. Ten min later the rats were killed and sections 
of their livers were processed for autoradiography as 
detailed in the methods section. H, hepatocytes, EC, 
endothelial cell, KC, Kupffer cell. Bar: 2 µm.
A 
B BMC Physiology 2004, 4:13 http://www.biomedcentral.com/1472-6793/4/13
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microscopy showed that most of the lipase was in the
spaces of Disse. The immunofluorescence was strongest in
the portal areas, indicating that the lipase was extracted
soon after it entered the liver. Most of the staining was
over hepatocytes. With time the immunofluorescence
shifted to a granular pattern, indicating that the enzyme
had been internalized. The internalization may have
occurred with lipase bound to HSPG, as demonstrated
Distribution of injected, inactive bovine LPL in livers, and the effect of heparin Figure 5
Distribution of injected, inactive bovine LPL in livers, and the effect of heparin All sections are 15 min after injec-
tion of inactive bovine LPL. The sections in panels A and C are from rats that did not receive heparin; the sections in panel B 
and D are from rats that had been given heparin five min before the lipase. Green colour represents staining of LPL by the rab-
bit polyclonal antibody. Red colour represents staining of Kupffer cells by the ED2 antibody. Panels C and D show both stain-
ings. The magnification was × 20 in panels A and B; × 60 + zooming in panels C and D.BMC Physiology 2004, 4:13 http://www.biomedcentral.com/1472-6793/4/13
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with cultured fibroblasts and with hepatocytes [32,35,36]
and/or with lipase bound to LRP as suggested by several
authors [24,25,35,37]. In fibroblasts, both these pathways
contribute to LPL internalization [38]. The lipase may
well recycle as demonstrated by Heeren et al in experi-
ments with cultured hepatocytes [39,40]. The immunos-
taining gradually faded with time indicating that the
lipase was degraded, in accord with previous studies, and
with the decrease of 125I-radioactivity in the liver observed
in the present study.
Inactive LPL, as prepared here, was taken up in Kupffer
cells. Most of the LPL in plasma is inactive [8,10] and
there is inactive LPL also in the tissues [19]. The nature
and metabolic significance of this inactive LPL is not clear.
Western blot analysis indicates that it is full-length LPL
[7]. On heparin-agarose it elutes in the position expected
for monomeric LPL [7]. Gel filtration of plasma indicates
that it is associated with the lipoproteins [8]. The turnover
of inactive LPL does not appear to be much influenced by
heparin [6,8,13]. Earlier studies had shown that injected,
inactive LPL is rapidly bound and degraded in the liver,
both in vivo [13] and on perfusion through an isolated
liver [14]. In these studies the inactive lipase was
produced by complete denaturation in 6 M guanidinium
chloride. In the present study the inactive lipase was gen-
tly prepared by incubation in rat plasma at 45°C. This
probably results in dissociation to inactive but still folded
monomers [41,42]. Our preliminary experiments had
shown that under these conditions the enzyme slowly lost
its catalytic activity. After 90 min, the time used here, less
than 5 % of the activity remained. In terms of clearance
rate and tissue distribution, the present preparation
behaved as the fully denatured lipase used in previous
studies. Whether any of these lipase preparations faith-
fully reproduces the metabolic behaviour of the inactive
lipase present in plasma is not clear. A recent study has
defined several conformational states of the LPL mole-
cule, and the kinetics of conformational transitions [42].
Before heparin, the ratio of LPL activity to LPL mass was
about 0.2 mU/ng in liver and 0.3 mU/ng in blood (Table
1). After heparin, the specific activity for LPL in plasma
increased to about 1.2, indicating that heparin released
mainly or almost exclusively the active form of the lipase
as has been shown to be the case in humans [7]. In the
liver, however, the ratio stayed well below one. At the 60
min time point LPL mass had increased by about 500 ng/
g, but LPL activity had only increased by about 240 mU.
This indicates that the lipase loses catalytic activity after it
is taken up in the liver, but is degraded more slowly. These
observations are in accord with earlier studies. Chajek-
Shaul et al. perfused rat livers with LPL-containing media
and found that the enzyme lost its catalytic activity soon
after binding/uptake in liver [43]. Wallinder et al com-
pared the uptake and degradation of 125I-labeled LPL in
liver to that for asialofetuin, which is taken up by the
galactose receptor [13]. The half-life for asialofetuin was
about 15 min, whereas that for the lipase was longer,
about one hour.
To explore the source of LPL released into plasma and
taken up by the liver we measured LPL activity in adipose
tissue and heart before and after injection of heparin. In
fed rats there was a large decrease of LPL activity in adi-
pose tissue, in accord with a previous study [6]. From
these data and the tissue weights at least 7000 mU LPL
activity was washed out from white adipose tissue during
the first 20 min after heparin. To this should be added an
unknown amount of LPL washed out from other tissues.
During the same time the LPL activity increased by the
1600 mU in the liver and about 5100 mU in blood. These
data indicate that the dominant source of LPL released to
plasma in fed rats is the white adipose tissue. Post-heparin
LPL activity was lower in fasted than in fed rats, less than
half, in accord with previous studies [18,20]. LPL activity
in adipose tissue is suppressed during fasting, and we did
not find any significant loss of activity after heparin.
Hence, the adipose tissue releases much less LPL activity
into plasma in fasted than in fed rats. The main contribu-
tors are presumably heart and skeletal muscle. We
observed a large washout of LPL activity from heart in the
fasted rats, about 40%. In other studies we have noted a
similar washout from the Soleus muscle. Kuwajima et al
perfused some of the rat hindlimb muscles (gastrocne-
mius, soleus and plantaris) with heparin in situ and
observed a large release in fasted but not in fed rats [20].
These data suggest that in fasted rats, the main source of
LPL released into plasma by heparin are skeletal muscles
and heart.
LPL in plasma is bound to lipoproteins and it has been
suggested that the lipase serves as a ligand for binding and
uptake of lipoproteins in the liver. Chevreuil et al injected
doubly labelled chylomicrons to rats shortly after heparin
[44]. The results showed accelerated lipolysis of the trig-
lyceride moiety of the chylomicrons, as expected. In addi-
tion, clearance of chylomicron remnants, as traced by
retinyl esters, was greatly accelerated. Together with the
present results this suggests that after heparin, the large
increase of LPL in blood may accelerate the hepatic uptake
of some lipoproteins.
Conclusions
• In the liver, the active form of LPL initially binds to sinu-
soidal surfaces but then transfers to and is taken up
mainly in hepatocytes
• An inactive form of LPL, presumably monomers, was
mainly taken up in Kupffer cellsBMC Physiology 2004, 4:13 http://www.biomedcentral.com/1472-6793/4/13
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• Heparin retards the uptake of active LPL in liver, but
there are heparin insensitive binding sites for LPL both on
hepatocytes and on Kupffer cells
• Release of LPL into blood by heparin results in acceler-
ated transport of the lipase to the liver
• The observation that rat liver contained substantial
amounts of LPL, most of which was inactive, is in accord
with the hypothesis that one route for turnover for
endothelial LPL is transport to and degradation in the
liver
• The observations that most of the LPL in blood is inac-
tive, that injected inactive bovine LPL located to Kupffer
cells, and that the immunostaining for endogenous LPL
was more intense over Kupffer cells than over hepatocytes
suggest that a substantial fraction of the transport from
extrahepatic tissues occurs with LPL that has lost its
activity.
• The main source of LPL released into plasma and taken
up by the liver in fed rats is the adipose tissue, whereas in
fasted rats the main sources are heart and skeletal muscles.
Methods
Animals
Male Sprague-Dawley rats (Moellegard Breeding centre,
Denmark) weighing 180–220 g were used. They were kept
on a standard pellet diet in a 12-hour light cycle. In order
not to disturb blood circulation or the metabolic
functions of the liver, we performed all experiments on
unanaesthetized rats. They were killed through decapita-
tion at the time of tissue removal. Injections were made in
the tail vein. Mean liver weight for the rats was about 9 g.
In some of the rats we dissected out all visible adipose tis-
sue. The mean total weight was 14 g, including fibrous tis-
sue removed with the subcutaneous adipose tissue. To
correct values for LPL mass/activity in the liver we used an
estimated figure of 3% for the amount of blood plasma
remaining in the liver after exsanguination. This was
based on earlier experiments with 125I-albumin and Cr51-
labeled red blood cells [45,46]. The local Animals Care
Committee in Umeå approved all animal procedures.
Materials
Vectashield mounting medium was from Vector Laborato-
ries, Burlingame, CA. Tissue-Tec OCT compound was pur-
chased from Sakura Finetek Europe BV, Zoeterwoude, The
Netherlands. Microscope slides and cover slips were from
Menzel – Gläser, Germany. Plasma, used in the prepara-
tion of catalytically inactive LPL, was taken from fasted
rats with EDTA as anticoagulant. Heparin was obtained
from Leo Pharma AB, Malmö, Sweden. The dose given
was 500 IU/kg body weight.
Lipase and antibody preparations
LPL was purified from bovine milk as previously
described [47] and was labeled with 125I using the lac-
toperoxidase/glucose oxidase method [13]. The labeled
LPL was separated from damaged protein and free iodine
by chromatography on heparin-Sepharose using a gradi-
ent of NaCl. The labeled preparations were stored at -
70°C in the presence of 2 mg BSA per ml. The specific
activity of the labeled LPL was approximately 10 000 cpm/
ng. Inactive LPL for the electron microscopy study was
prepared by dissociation in guanidinium hydrochloride
as described [13]. To find suitable conditions to prepare
inactive LPL for the immunofluorescence experiments, we
diluted bovine LPL in rat plasma to the concentration we
would later use in the in vivo experiments and incubated
this at different temperatures. On incubation at 37°C the
LPL activity remained essentially stable for one hour. At
higher temperatures the lipase became unstable. Based on
these results we decided to use 45°C for gentle inactiva-
tion of LPL aimed to prevent aggregation of the enzyme.
Chromatography on heparin-Sepharose of active and
inactivated LPL showed, as expected [19], that the active
form of LPL eluted around 1 M NaCl, while the inactive
form(s) eluted earlier in the salt gradient. After 30 min at
45°C most of the lipase eluted early in the gradient. Only
about 20 % remained in the form with high heparin affin-
ity. At 60 min this form had been reduced to 8 % and after
90 min it had virtually disappeared. From this we decided
to use incubation at 45°C for 90 min to transform LPL to
the inactive (presumably monomeric) form with low
affinity for heparin. A trace amount of 125I-labeled LPL
was included in the preparation, to enable us to follow the
distribution and metabolism of the injected material.
Each rat received about 40 µg lipase protein, except in the
electron microscopy studies where only a trace amount of
the labeled lipase was injected.
Antibodies against bovine LPL were raised in a chicken
(chicken no 225) and IgG were isolated from egg yolks as
previously described [48]. Antibodies against bovine LPL
were also raised in a rabbit and IgG were isolated on a
Protein A-Sepharose column. Both the chicken and the
rabbit antibodies were affinity purified on LPL-Sepharose.
They were eluted with 0.2 M glycine at pH 2.7, and 50 mM
diethylamine at pH 12, respectively, and immediately dia-
lysed against 10 mM Tris/HCl, pH 7.4. Monoclonal anti-
body 5D2 to LPL was a kind gift from Dr. J. Brunzell,
Seattle. A mouse monoclonal antibody (ED2) against a
surface antigen expressed on rat Kupffer cells was
obtained from Becton Dickinson, San Diego, CA. Goat
anti-rabbit IgG labeled with Alexa Fluor 488, goat anti-
chicken IgG labeled with Alexa Fluor 488, and goat anti-
mouse IgG labeled with Alexa Fluor 546 were from Molec-
ular Probes, Leiden, The Netherlands. Goat IgG, used for
control sections, was from Sigma, St.Louis, MO.BMC Physiology 2004, 4:13 http://www.biomedcentral.com/1472-6793/4/13
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Preparation of tissue for immunofluorescence studies and 
confocal microscopy
Small pieces of liver were mounted in Tissue – Tec OCT
and snap frozen in propane chilled with liquid nitrogen.
The tissue pieces were then stored at -70°C until section-
ing. Cryosections were fixed for 10 min in 4 % parafor-
maldehyde. After rinsing, the sections were blocked in 5
% goat serum for 10 min and then incubated overnight
with the primary antibody. All these procedures were
made at room temperature. Incubation with the second-
ary antibody was then for 30 min at 37°C. The sections
were rinsed in 0.01 M phosphate 0.15 M NaCl at pH 7.4
and mounted in Vectashield medium (Vector laborato-
ries, Burlingame, CA). The immunostained samples were
analyzed by confocal laser scanning microscopy (Leica
SP2 or Nikon Eclipse E 800). To avoid potential signal
crossover the two fluorophores were sequentially
scanned. Data were collected with sequential laser excita-
tion to eliminate bleed through and with confocal param-
eters such as pinhole size set to minimize the thickness of
the optical sections. The images were digitally optimized
using the Adobe Photoshop software.
Electron microscopy
For autoradiographic studies, 125I-labeled LPL was
injected to rats and 10 min later, the livers were perfused
with 2% paraformaldehyde, 2.5% glutaraldehyde in 0.1
M phosphate buffer at pH 7.4 for 10 min. After fixation
the livers were washed in 0.1 M phosphate buffer, cut in
small pieces, dehydrated through graded acetone solu-
tions and embedded in Spurr resin. Postfixation with 1%
osmium tetroxide was not performed due to its known
effect of fading latent images in autoradiography.
Ultrathin sections, 70 nm thick, were collected over Form-
var-carbonated copper grids. These sections were coated
with a monolayer of Ilford L4 nuclear emulsion, diluted
1:4 with distilled water, by means of a tungsten wire loop
following the "loop interference" technique. After an
exposure of 8 months, the silver grains were revealed with
Phenidon development. Sections were stained with ura-
nyl acetate and lead citrate and examined in a Hitachi MT
800 electron microscope at 75 kV. Quantitative analysis
was performed by counting the number of silver grains
per area in each experimental condition. The area ana-
lyzed was about 25 × 104 µm2.
Lipase assays
The activities of LPL and of hepatic lipase were deter-
mined as described [49]. In the assay for LPL the substrate
was an emulsion of soybean triglycerides and a trace
amount 3H oleic acid-labeled triolein in egg yolk phos-
pholipids. Hepatic lipase (HL) was inhibited by incuba-
tion of the samples on ice for two h with rabbit anti-HL
IgG. In the HL assay, LPL is inactivated by 1 M NaCl. Both
assays were run at 25°C for 30 min. All determinations
were carried out in triplicate. The activities are expressed
in mU/ml plasma. One mU corresponds to 1 nmol of
fatty acid released / min. All determinations were carried
out in triplicates.
Plasma samples were stored frozen at -70°C before the
analysis. Tissue samples were rinsed in cold 0.9 % NaCl,
blotted dry, weighed and then immediately frozen in
liquid nitrogen in 9 volumes of buffer at pH 8.2 contain-
ing per ml: 1 mg BSA, 10 mg Triton X-100, 1 mg SDS, 5 IE
heparin, and protease inhibitor Complete Mini (Roche) 1
tablet / 50 ml buffer. They were stored at -70°C and later
thawed and homogenized with a Polytron homogenizer
(PT-MR 3000; Kinematica AG, Littau, Switzerland). The
homogenates were centrifuged for 15 min at 3000 rpm in
a Beckman Microfuge and the supernatants were used for
the assays. For assay of LPL in liver and post-heparin
plasma, the activity of hepatic lipase was suppressed by
incubating the extract with an excess of anti-HL immu-
noglobulins before assay.
Detergent containing extraction buffers are needed to sol-
ubilize and stabilize active and inactive forms of LPL effi-
ciently [19,50], but the detergents may interfere with the
assay. Bergö and Olivecrona [19] used the same assay con-
ditions as in the present study and found that the assay
system tolerated at least 10 µl of the detergent buffer with-
out any decrease in LPL action. We have repeated these
studies in the context of the present experiments. With
extracts from adipose tissue, the assay system showed
good linearity between the amount of extract added and
the lipase activity displayed, but with extracts from heart,
kidney or liver there was a definite nonlinearity. Our inter-
pretation is that other tissue proteins, solubilized by the
detergents, interfere. We have therefore used a small vol-
ume of tissue extract (usually 2 µL), to stay within, or close
to, the linear range of the assay. To explore the recovery of
LPL activity in liver extracts as prepared here, we added
purified bovine LPL to the homogenate which was then
treated and assayed as the other samples. The recovery of
the added bovine LPL was complete within experimental
error.
LPL protein mass was measured by an ELISA, using
chicken antibodies for capture and the monoclonal 5D2
antibody coupled to peroxidase for detection [19]. Bovine
LPL was used as standard.
List of abbreviations
LRP – low density lipoprotein receptor-related protein,
LPL – lipoprotein lipase, HSPG – heparan sulphate prote-
oglycan, HL – hepatic lipase, ELISA – enzyme-linked
immunoassay, BSA – bovine serum albumin, SDS –
sodium dodecyl sulphate, VLDL – very low density
lipoproteinBMC Physiology 2004, 4:13 http://www.biomedcentral.com/1472-6793/4/13
Page 12 of 13
(page number not for citation purposes)
Authors' contributions
LN carried out the immunolocalization studies, C L-I car-
ried out the electron microscopic studies, SV participated
in the design of the study and supervised the electron
microscopy, JG carried out the studies on wash-out of LPL
from tissues after heparin, TO conceived of the study, par-
ticipated in its design and drafted the manuscript. GO par-
ticipated in the design of the study and coordinated the
work. All authors read and approved the final manuscript.
Acknowledgements
This study was supported by grants from the Swedish Medical Research 
Council 03X-727 and 13X-12203. We thank Dr Inga Hägerstrand, Umeå 
University Hospital, for help with liver morphology, David Bellido, Scientific 
and Technical Services of the University of Barcelona, for technical help 
with autoradiography, Ann-Sofie Jacobsson for carrying out all lipase assays, 
Åsa Lundsten for preparing the antibodies Solveigh Nilsson for preparing 
the bovine lipase, and Toralph Ruge for labeling it with 125I.
References
1. Goldberg IJ: Lipoprotein lipase and lipolysis: Central roles in
lipoprotein metabolism and atherogenesis. J Lipid Res 1996,
37:693-707.
2. Olivecrona T, Olivecrona G: Lipoprotein and hepatic lipases in
lipoprotein metabolism. In Lipoproteins in health and disease Edited
by: Betteridge DJ, Illingworth DR and Shepherd J. London, Arnold;
1999:223-246. 
3. Semenkovich CF, Chen SH, Wims M, Luo CC, Li WH, Chan L: Lipo-
protein lipase and hepatic lipase mRNA tissue specific
expression, developmental regulation, and evolution. J Lipid
Res 1989, 30:423-431.
4. Camps L, Reina M, Llobera M, Vilaró S, Olivecrona T: Lipoprotein
lipase: cellular origin and functional distribution. Am J Physiol
1990, 258:C673-C681.
5. Saxena U, Klein MG, Goldberg IJ: Transport of lipoprotein lipase
across endothelial cells.  Proc Natl Acad Sci U S A 1991,
88:2254-2258.
6. Wu G, Olivecrona G, Olivecrona T: The distribution of lipopro-
tein lipase in rat adipose tissue. Changes with nutritional
state engage the extracellular enzyme.  J Biol Chem 2003,
278:11925-11930.
7. Olivecrona G, Hultin M, Savonen R, Skottova N, Lookene A, Tugrul
Y, Olivecrona T: Transport of lipoprotein lipase in plasma and
lipoprotein metabolism. In Atherosclerosis X Edited by: Woodford
FP, Davignon J and Sniderman AD. Elsevier; 1995:250-253. 
8. Vilella E, Joven J, Fernández M, Vilaró S, Brunzell JD, Olivecrona T,
Bengtsson-Olivecrona G: Lipoprotein lipase in human plasma is
mainly inactive and associated with cholesterol-rich
lipoproteins. J Lipid Res 1993, 34:1555-1564.
9. Tornvall P, Olivecrona G, Karpe F, Hamsten A, Olivecrona T: Lipo-
protein lipase mass and activity in plasma and their increase
after heparin are separate parameters with different rela-
tions to plasma lipoproteins. Arterioscler Thromb Vasc Biol 1995,
15:1086-1093.
10. Kobayashi J, Saito K, Fukamachi I, Taira K, Takahashi K, Bujo H, Saito
Y: Pre-heparin plasma lipoprotein lipase mass: correlation
with intra-abdominal visceral fat accumulation. Horm Metab
Res 2001, 33:412-416.
11. Bagby GJ: Heparin-independent release of lipoprotein lipase
from perfused rat hearts. Biochim Biophys Acta 1983, 753:47-52.
12. Karpe F, Olivecrona T, Olivecrona G, Samra JS, Summers LKM, Hum-
phreys SM, Frayn KN: Lipoprotein lipase transport in plasma:
role of muscle and adipose tissues in regulation of plasma
lipoprotein lipase concentrations.  J Lipid Res 1998,
39:2387-2393.
13. Wallinder L, Peterson J, Olivecrona T, Bengtsson-Olivecrona G:
Hepatic and extrahepatic uptake of intravenously injected
lipoprotein lipase. Biochim Biophys Acta 1984, 795:513-524.
14. Vilaró S, Llobera M, Bengtsson-Olivecrona G, Olivecrona T: Lipo-
protein lipase uptake by the liver: localization, turnover, and
metabolic role. Am J Physiol 1988, 254:G711-G722.
15. Peterson J, Olivecrona T, Bengtsson-Olivecrona G: Distribution of
lipoprotein lipase and hepatic lipase between plasma and tis-
sues: effect of hypertriglyceridemia. Biochim Biophys Acta 1985,
837:262-270.
16. Chevreuil O, Hultin M, Østergaard PB, Olivecrona T: Depletion of
lipoprotein lipase after heparin administration.  Arterioscler
Thromb 1993, 13:1391-1396.
17. Näsström B, Olivecrona G, Olivecrona T, Stegmayr BG: Lipopro-
tein lipase during continuous heparin infusion: Tissue stores
become partially depleted. J Lab Clin Med 2001, 138:206-213.
18. Ruge T, Bergö M, Hultin M, Olivecrona G, Olivecrona T: Nutritional
regulation of binding sites for lipoprotein lipase in rat heart.
Am J Physiol Endocrinol Metab 2000, 278:E211-E218.
19. Bergö M, Olivecrona G, Olivecrona T: Forms of lipoprotein lipase
in rat tissues: In adipose tissue the proportion of inactive
lipase increases on fasting. Biochem J 1996, 313:893-898.
20. Kuwajima M, Foster DW, McGarry JD: Regulation of lipoprotein
lipase in different rat tissues. Metabolism 1988, 37:597-601.
21. Wallinder L, Bengtsson G, Olivecrona T: Rapid removal to the
liver of intravenously injected lipoprotein lipase. Biochim Bio-
phys Acta 1979, 575:166-173.
22. Hultin M, Olivecrona G, Olivecrona T: Effect of protamine on
lipoprotein lipase and hepatic lipase in rats. Biochem J 1994,
304:959-966.
23. Gliemann J: Receptors of the low density lipoprotein (LDL)
receptor family in man. Multiple functions of the large family
members via interaction with complex ligands.  Biol Chem
Hoppe Seyler 1998, 379:951-964.
24. Verges M, Bensadoun A, Herz J, Belcher JD, Havel RJ: Endocytosis
of hepatic lipase and lipoprotein lipase into rat liver hepato-
cytes in vivo is mediated by the low density lipoprotein
receptor-related protein. J Biol Chem 2004, 279:9030-6.
25. Espirito Santo SM, Pires NM, Boesten LS, Gerritsen G, Bovenschen
N, Willems VD, Jukema JW, Princen HM, Bensadoun A, Li WP, Herz
J, Havekes LM, Van Vlijmen BJ: Hepatic Low-Density Lipoprotein
Receptor-Related Protein Deficiency in Mice Increases
Atherosclerosis Independent of Plasma Cholesterol.  Blood
2004, 103:3777-3782.
26. Nykjær A, Bengtsson-Olivecrona G, Lookene A, Moestrup SK,
Petersen CM, Weber W, Beisiegel U, Gliemann J: The a2-mac-
roglobulin receptor/low density lipoprotein receptor-
related protein binds lipoprotein lipase and - migrating very
low density lipoprotein associated with the lipase. J Biol Chem
1993, 268:15048-15055.
27. Hanyu O, Miida T, Obayashi K, Ikarashi T, Soda S, Kaneko S, Hirayama
S, Suzuki K, Nakamura Y, Yamatani K, Aizawa Y: Lipoprotein lipase
(LPL) mass in preheparin serum reflects insulin sensitivity.
Atherosclerosis 2004, 174:385-390.
28. Vilaró S, Ramírez I, Bengtsson-Olivecrona G, Olivecrona T, Llobera
M: Lipoprotein lipase in liver. Release by heparin and immu-
nocytochemical localization.  Biochim Biophys Acta 1988,
959:106-117.
29. Bengtsson-Olivecrona G, Olivecrona T, Hultin M, Liu G, Vilaró S:
Uptake of lipoprotein lipase in the liver. Mechanism and
physiological relevance. In Hepatic endocytosis of lipids and proteins
Edited by: Windler E and Greten H. Munich, Zuckschwerdt Verlag;
1993:292-298. 
30. Bernfield M, Götte M, Park PW, Reizes O, Fitzgerald ML, Lincecum J,
Zako M: Functions of cell surface heparan sulfate
proteoglycans. Annu Rev Biochem 1999, 68:729-777.
31. Kolset SO, Salmivirta M: Cell surface heparan sulfate proteogly-
cans and lipoprotein metabolism.  Cell mol life sci 1999,
56:857-870.
32. Casaroli-Marano RP, García R, Vilella E, Olivecrona G, Reina M, Vilaró
S: Binding and intracellular trafficking of lipoprotein lipase
and triacylglycerol-rich lipoproteins by liver cells. J Lipid Res
1998, 39:789-806.
33. Stow JL, Kjellén L, Unger E, Höök M, Farquhar MG: Heparan sulfate
proteoglycans are concentrated on the sinusoidal plasmale-
mmal domain and in intracellular organelles of hepatocytes.
J Cell Biol 1985, 100:975-980.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Physiology 2004, 4:13 http://www.biomedcentral.com/1472-6793/4/13
Page 13 of 13
(page number not for citation purposes)
34. Mahley RW, Ji ZS: Remnant lipoprotein metabolism: key path-
ways involving cell- surface heparan sulfate proteoglycans
and apolipoprotein E. J Lipid Res 1999, 40:1-16.
35. Sehayek E, Olivecrona T, Olivecrona G, Vlodavsky I, Levkovitz H,
Avner R, Eisenberg S: Lipoprotein lipase metabolism in HepG2
and other cells in culture: Binding to heparan sulfate is an
obligatory and critical step for further cellular catabolism of
the enzyme. Atherosclerosis 1995, 114:1-8.
36. Fernandez-Borja M, Bellido D, Makiya R, David G, Olivecrona G,
Reina M, Vilaró S: Actin cytoskeleton of fibroblasts organizes
surface proteoglycans that bind basic fibroblast growth fac-
tor and lipoprotein lipase. Cell Motil Cytoskeleton 1995, 30:89-107.
37. Beisiegel U, Weber W, Bengtsson-Olivecrona G: Lipoprotein
lipase enhances the binding of chylomicrons to low density
lipoprotein receptor-related protein. Proc Natl Acad Sci U S A
1991, 88:8342-8346.
38. Sehayek E, Wang XX, Vlodavsky I, Avner R, Levkovitz H, Olivecrona
T, Olivecrona G, Willnow TE, Herz J, Eisenberg S: Heparan sulfate-
dependent and low density lipoprotein receptor- related
protein-dependent catabolic pathways for lipoprotein lipase
in mouse embryonic fibroblasts. Isr J Med Sci 1996, 32:449-454.
39. Heeren J, Weber W, Beisiegel U: Intracellular processing of
endocytosed triglyceride-rich lipoproteins comprises both
recycling and degradation. J Cell Sci 1999, 112:349-359.
40. Heeren J, Grewal T, Jackle S, Beisiegel U: Recycling of apolipopro-
tein E and lipoprotein lipase through endosomal compart-
ments in vivo. J Biol Chem 2001, 276:42333-43338.
41. Olivecrona G, Lookene A: Noncatalytic functions of lipoprotein
lipase. Methods Enzymol 1997, 286:102-116.
42. Lookene A, Zhang L, Hultin M, Olivecrona G: Rapid subunit
exchange in dimericlipoprotein lipase and properties of the
inactive monomer. J Biol Chem 2004.
43. Chajek-Shaul T, Friedman G, Ziv E, Bar-On H, Bengtsson-Olivecrona
G: Fate of lipoprotein lipase taken up by the rat liver: evi-
dence for a conformational change with loss of catalytic
activity. Biochim Biophys Acta 1988, 963:183-191.
44. Chevreuil O, Hultin M, Østergaard PB, Olivecrona T: Biphasic
effects of low-molecular-weight and conventional heparins
on chylomicron clearance in rats.  Arterioscler Thromb 1993,
13:1397-1403.
45. Hultin M, Savonen R, Olivecrona T: Chylomicron metabolism in
rats: Lipolysis, recirculation of triglyceride-derived fatty
acids in plasma FFA, and fate of core lipids as analyzed by
compartmental modelling. J Lipid Res 1996, 37:1022-1036.
46. Hultin M, Bengtsson-Olivecrona G, Olivecrona T: Release of lipo-
protein lipase to plasma by triacylglycerol emulsions. Com-
parison to the effect of heparin.  Biochim Biophys Acta 1992,
1125:97-103.
47. Bengtsson-Olivecrona G, Olivecrona T: Phospholipase activity of
milk lipoprotein lipase. Methods Enzymol 1991, 197:345-356.
48. Olivecrona T, Bengtsson G: Immunochemical properties of lipo-
protein lipase. Development of an immunoassay applicable
to several mammalian species.  Biochim Biophys Acta 1983,
752:38-45.
49. Olivecrona T, Olivecrona G: Determination and clinical signifi-
cance of lipoprotein lipase and hepatic lipase. In Handbook of
lipoprotein testing Volume 22. 2nd edition. Edited by: Rifai N, Warnick
GR and Dominiczak MH. Washington DC, AACC Press;
2000:479-497. 
50. Semb H, Olivecrona T: Nutritional regulation of lipoprotein
lipase in guinea pig tissues.  Biochim Biophys Acta 1986,
876:249-255.